Angli Xue

May 16, 2024 | medrxiv.org | Wei Zhou |Anna SE Cuomo |Angli Xue |Masahiro Kanai

B.M.N. is a member of the scientific advisory board at Deep Genomics and Neumora. M.D. is a founder of Maze Therapeutics. W.Z. was supported by the National Human Genome Research Institute of the National Institutes of Health under award number K99/R00HG012222. A.C. was supported by an EMBO Long Term Postdoctoral Fellowship (EMBO ALTF 424-2022). B.M.N. is supported by the Novo Nordisk Foundation (NNF21SA0072102) and R01MH101244. BMN and GC are supported by R37MH107649.

Mar 12, 2024 | nature.com | Angli Xue |Zhihong Zhu |Huanwei Wang |Peter M. Visscher |Jian Zeng

AbstractSubstance use behaviours (SUB) including smoking, alcohol consumption, and coffee intake are associated with many health outcomes. However, whether the health effects of SUB are causal remains controversial, especially for alcohol consumption and coffee intake. In this study, we assess 11 commonly used Mendelian Randomization (MR) methods by simulation and apply them to investigate the causal relationship between 7 SUB traits and health outcomes.

Feb 23, 2023 | genomebiology.biomedcentral.com | Angli Xue |Seyhan Yazar |Drew Neavin |Joseph Powell

Three single-cell datasets were used in this study to explore the performance of the PEER and PCA methods. The OneK1K consortium [14] is a population-scale single-cell RNA-seq dataset collected in Tasmania, Australia. This cohort includes 982 individuals, each with gene expression profiling for ~ 1000 (mean = 1297.0, standard deviation = 23.6) peripheral blood mononuclear cells (PBMCs).